A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Fortress Biotech, Inc. (Nasdaq: FBIO) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven...
During this fireside we welcome Unicycive Therapeutics. Unicycive (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding...
During this fireside we welcome Nexalin Technology. Nexalin (Nasdaq: NXL) designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and...
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive...
Milestone Scientific Inc. (NYSE: MLSS) is a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled...
BioSyent, Inc. (TSXV: RX / OTC: BIOYF) is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have...
During this fireside we welcome NeuroSense Therapeutics. NeuroSense (NASDAQ: NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that...
During this fireside we welcome Modular Medical. Modular Medical, Inc. (NASDAQ:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to...
Reviva (Nasdaq: RVPH) is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current...
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR...
During this fireside chat Joe Dorame, Managing Partner, Lytham Partners, and Brooks O'Neil, Lake Street Capital Markets chat with Richard DiIorio, Chief Executive Officer of InfuSystem Holdings, Inc. InfuSystem (NYSE American: INFU) is a leading national health care...
During this presentation we welcome, Shuttle Pharma. Shuttle Pharma (Nasdaq: SHPH) is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). The Company's mission is...
During this presentation we welcome, PolyPid. PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical...
During this presentation we welcome, Kiora Pharmaceuticals. Kiora (Nasdaq: KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. This Company Webcast was recorded during the Lytham...
During this presentation we welcome, Jaguar Health. Jaguar Health (Nasdaq: JAGX) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals...
GARDNER, Mass., Oct. 01, 2024 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced today it will participate in a webcast...
Cadrenal Therapeutics (Nasdaq: CVKD) is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed...
Conference Call Scheduled for today, September 30, 2024, at 5:00pm ET.GARDNER, Mass., Sept. 30, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace...
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities...
GARDNER, Mass., Sept. 24, 2024 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a...
Company to Showcase Cutting-Edge Innovations at Booth #4510CARLSBAD, Calif., Sept. 24, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery,...
PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for...
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacture of proteins for use in non-pharmaceutical...
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted three equity awards, previously...
DENVER, CO / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter,...
CARMEL, Ind., Sept. 19, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a...
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic...
CARLSBAD, CA, Sept. 11, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, is excited to announce a recorded ZOOM call on...
WINTER SPRINGS, Fla., Sept. 10, 2024 -- IRADIMED CORPORATION ("Iradimed") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8th Annual...
CARLSBAD, Calif., Sept. 05, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced its participation in the upcoming...
In this episode, we are featuring Dror Ortho-Design, Inc. (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a single custom-made smart...
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic...
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual...
CARMEL, Ind., Aug. 27, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical...
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by independent...
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) ("Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the...
PONTE VEDRA, Fla., Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., Aug. 21, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves...
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a...
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will present data from its FOCUS Phase 3 study at the 2024...
SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics,...
PONTE VEDRA, Fla., Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
GARDNER, Mass., Aug. 14, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has entered into securities purchase...
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the...
PORTLAND, Maine, Aug. 13, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
CARMEL, Ind., Aug. 13, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical...
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted one equity award, previously approved...
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on...
Conference call will be held today, Friday, August 9 at 9:00 am ETCarmel, Ind., Aug. 09, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating...
DENVER, CO / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted...